The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Joint by Joint

Joint by Joint

November 1, 2006 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Maybe it’s the soft trace of a southern accent, or the respect he accords even ordinary questions. Whatever the clue, you quickly perceive that John T. Sharp, MD, is both a gracious and an authoritative person. Perhaps it is this disarming combination of qualities that most endears Dr. Sharp to his fellow rheumatologists, many of whom regard him as a giant in the field of RA—and not just because he created the Sharp score, a standardized outcome measure for tracking RA progression.

You Might Also Like
  • Remembrance of John Sharp, MD, Rheumatologist Extraordinaire
  • Rheumatology Coding Corner Question: Joint Injection with Ultrasound Guidance, No Office Visit
  • Secukinumab Inhibits Structural Joint Damage in Active PsA
Explore This Issue
November 2006
Also By This Author
  • European Beacon for Rheumatology

“I have known John for 15 years,” says Lee S. Simon, MD, associate clinical professor of medicine at Harvard Medical School in Boston and former division director of the Arthritis, Analgesic, and Ophthalmologic Drug Product Division at the Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research. “But, in those years, he has always been this unassuming, modest kind of guy with impeccable manners. He never interrupts anybody, he never pushes his theory in front of somebody else’s theory, and he allows people to talk. Even when there is an argument, he just continues to ‘plug away’ on the evidence, which he knows quite well.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Vibeke Strand, MD, adjunct clinical professor of medicine in the Division of Immunology at Stanford University and a biopharmaceutical consultant who has worked with Dr. Sharp on numerous development programs on treatments for RA, agrees. “He’s very modest and unassuming, and he’s always bringing people together,” says Dr. Strand. “He’s a real delight, and it’s really a pleasure always to continue to learn from and work with him.”

Throughout his nearly six decade–long career, Dr. Sharp’s keen intelligence and passion for standardized outcome measures have led him on a path of discovery that some have called courageous. According to other top rheumatologists and drug researchers interviewed for this article, the last 15 years of pharmacologic advances in RA would not have been possible without a quantitative measure for evaluating disease progression—a measure made possible by Dr. Sharp’s seminal work in the 1960s and early 1970s.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

How did the idea for such a method come about? And how did Dr. Sharp pioneer this method of quantitatively assessing erosions and joint space narrowing to measure progression of RA over time? During two recent afternoon conversations from his home on Bainbridge Island near Seattle, Dr. Sharp amiably agreed to talk about the influences on his career and the scoring technique he developed.

“I tell this story—and it’s almost true,” he begins wryly. “I sat down one afternoon and in a couple of hours designed the whole system. Of course, having designed it, it took six months, a year, maybe even a bit longer, to collect the data to show that it was an appropriate measure, and that it correlated with the features of clinical outcomes that were important.”

Throughout his nearly six decade–long career, Dr. Sharp’s keen intelligence and passion for standardized outcome measures have led him on a path of discovery that some have called courageous.

Of course, many events and influences led to that afternoon’s work, including Dr. Sharp’s reasons for entering the specialty in the first place.

Why Rheumatology?

As a young resident, Dr. Sharp had been fascinated with rheumatic fever. Realizing that he could not specialize in one disease, he began to consider cardiology, infectious disease, or rheumatology. Of the three specialties, he thought that rheumatology offered more challenges and began looking for a fellowship program.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Practice Management, Profiles Tagged With: Clinical research, Metrics, Outcome measures, Rheumatoid Arthritis (RA)Issue: November 2006

You Might Also Like:
  • Remembrance of John Sharp, MD, Rheumatologist Extraordinaire
  • Rheumatology Coding Corner Question: Joint Injection with Ultrasound Guidance, No Office Visit
  • Secukinumab Inhibits Structural Joint Damage in Active PsA
  • Predictors of RA Flare After Total Joint Arthroplasty

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)